This final section presents a distillation from the coverage above (with some additions there was no room to detail) in the form of Table . This lists compound and target guidelines for ADEV teams and their collaborators. The nonprofit LifeArc has struck a deal to sell a large block of its Keytruda royalties to a pension firm for $1.3 billion it will now use to support scientists at work developing new drugs and devices. The rich UK R&D scene has been a fertile ground for early stage work. This windfall of blockbuster cash will now bolster LifeArc's work in the field.